Jae B. Kim - Mar 13, 2024 Form 3 Insider Report for Design Therapeutics, Inc. (DSGN)

Role
Chief Medical Officer
Signature
/s/ Mustapha Parekh, Attorney-in-Fact
Stock symbol
DSGN
Transactions as of
Mar 13, 2024
Transactions value $
$0
Form type
3
Date filed
3/20/2024, 07:57 PM
Next filing
Oct 24, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding DSGN Common Stock 4.76K Mar 13, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding DSGN Stock Option (right to buy) Mar 13, 2024 Common Stock 315K $12.77 Direct F1
holding DSGN Stock Option (right to buy) Mar 13, 2024 Common Stock 115K $7.97 Direct F2
holding DSGN Stock Option (right to buy) Mar 13, 2024 Common Stock 175K $2.54 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option will vest as follows: 25% of the shares vested on January 24, 2023, and the balance will vest in equal monthly installments thereafter over a three year period.
F2 The shares subject to the option will vest as follows: 20% of the shares vested on February 1, 2024, 20% of the shares will vest in equal monthly installments over the following 12 months, 30% of the shares will vest in equal monthly installments over the following 12 months, and 30% of the shares will vest in equal monthly installments over the following 12 months.
F3 The shares subject to the option will vest as follows: 20% of the shares will vest on January 1, 2025, 20% of the shares will vest in equal monthly installments over the following 12 months, 30% of the shares will vest in equal monthly installments over the following 12 months, and 30% of the shares will vest in equal monthly installments over the following 12 months.